Navigation Links
Oncologists recognized by ESMO for outstanding contributions to cancer research and treatment
Date:9/19/2011

The European Society for Medical Oncology (ESMO) has honored three of Europe's leading medical oncologists with prestigious awards recognizing their achievements in clinical care and research.

"The eminent oncologists we are celebrating with these awards have each made enormous contributions to the care of patients with cancer," said Prof David Kerr, ESMO President. "We congratulate them and thank them for their unstinting efforts on behalf of others."

The 2011 ESMO Award has been granted to Prof Johann de Bono of The Institute of Cancer Research and The Royal Marsden's Hospital in the UK, for his outstanding contributions in translational and clinical research, innovative treatment, education and development of international guidelines for prostate cancer management.

"Prof de Bono has undertaken exceptional work in the development of a number of new innovative compounds for several new indications in oncology and has made important contributions to the development of new drugs in prostate cancer, particularly through excellence in translational research and study design," said Dr Josep Tabernero, Chair of the ESMO Fellowship and Award Committee.

The ESMO Award is conferred on an ESMO member who has made an outstanding contribution to the development of oncology in Europe and who recognizes the importance of promoting oncology as a specialty within the international community.

"This award is a great encouragement and will spur me on to continue to serve cancer patients," Prof de Bono said. "Drug development in oncology has made substantial strides forward over the last decade. While much still needs to be done, we can now be confident that much will be accomplished in the years ahead."

The Hamilton Fairley Award for 2011 has been awarded to Prof Rafael Rosell of the Catalan Institute of Oncology in Badalona, Spain. Prof Rosell is a leading figure in the field of lung cancer, who established a productive group of clinical and laboratory investigators in the Medical Oncology Department at Hospital Trias i Pujol, which has become one of the leading centers in lung cancer management.

"Prof Rosell's contributions range from tumor biology and prognostic and treatment-predictive markers, to clinical trials involving chemotherapy and targeted agents with careful dedication to personalized medicine," said Dr Tabernero.

The Hamilton Fairley Award commemorates one of the founding fathers of Medical Oncology in Europe and is presented to candidates who are internationally recognized for lifetime achievements in science and clinical/laboratory research.

"Nowadays, clinical achievements are basically propelled by translational research and therefore this award is a recognition of a multidisciplinary effort," Prof Rosell said. "It is a great honor for me to receive this award, but more importantly, I believe that the award is a recognition of the collective group of clinical and laboratory investigators, as well as statisticians and other key persons involved."

The ESMO Lifetime Achievement Award in 2011 goes to Prof Hans Jrg Senn of the Tumor and Breast Centre ZeTuP, in St Gallen, Switzerland.

"Prof Senn is being recognized for his work in organizing educational activities, which set the standards of care in breast cancer, mainly in relation to adjuvant treatment, as well as bringing prevention strategies to Medical Oncologists in Europe," said Prof Franco Cavalli, Chair of the ESMO Lifetime Achievement Award Committee. "His outstanding efforts through the organization of Consensus Conferences among breast cancer experts focused attention on addressing subtle questions in the adjuvant treatment of breast cancer, which presented a dilemma for practicing physicians."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert  

Related biology news :

1. Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test
2. UAB oncologists: HPV vaccine protects from cancer recurrence
3. UF oncologists fight leukemia with two-pronged therapy, clinical trials planned
4. Value of satellites recognized for conserving wetlands
5. Pollution at home lurks unrecognized, instead attributed to large-scale environmental disasters
6. Household exposure to toxic chemicals lurks unrecognized, researchers find
7. 13 UCR faculty members recognized by American Association for the Advancement of Science
8. Federal scientists recognized for contributions to knowledge of bird ecology and habitat
9. Biomedical engineering student recognized as IEEEs New Face of Engineering
10. Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements
11. UC Riverside entomologist recognized for research in citrus entomology
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Oncologists recognized by ESMO for outstanding contributions to cancer research and treatment
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: